Extended-release carbidopa-levodopa in Parkinson's disease

The Lancet Neurology

Volumn 12, Issue 4, 2013, Pages 325-326

  Rascol, Olivier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR;

CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG STABILITY; DYSKINESIA; HUMAN; LETTER; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE;

CARBIDOPA; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MOTOR SKILLS DISORDERS; PARKINSON DISEASE;

EID: 84875240144     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70039-5     Document Type: Letter

References (11)

1. Nutt JG Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa?. Mov Disord 2007, 22:1-9.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
3. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954. for the LARGO study group.
4. Olanow CW, Stern MB, Sethi K The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009, 72(suppl 4):S1-136.
5. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013, for the IPX066 ADVANCE-PD investigators, published online Feb 26. http://dx.doi.org/10.1016/S1474-4422(13)70025-5.
6. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011, 26:2246-2252.
7. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359: 1589-98.
8. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
9. Seeberger LC, Hauser RA Levodopa/carbidopa/entacapone in Parkinson's disease. Expert Rev Neurother 2009, 9:929-940.
10. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010, 68:18-27.
11. Coelho M, Ferreira JJ Late-stage Parkinson disease. Nat Rev Neurol 2012, 8:435-442.